Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Astrazeneca Pharma India Ltd (ASTRAZEN) is currently trading at 8,237.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
AstraZeneca Pharma India Limited (APIL) is a subsidiary engaged in manufacturing, distributing, and marketing pharmaceutical products, focusing on therapeutic areas like oncology, cardio metabolic, and respiratory care. The company has aligned with AstraZeneca PLC’s global therapeutic focus, driving significant market presence in India’s diabetes and cardiovascular segments through strategic partnerships and product launches. APIL's recent launch of innovative drugs like Transtuzumab Deruxtecan for breast cancer marks its significant entry into advanced oncology treatment. While regulatory interventions have influenced drug pricing, strategic responses like partnerships with Dr. Reddy's Laboratories and Sun Pharma enhanced APIL’s market access and portfolio reach. APIL continues its R&D expansion in Bangalore, reinforcing its role within AstraZeneca’s global research network.
Over the past 52 weeks, Astrazeneca Pharma India Ltd has traded between a low of ₹7,630.00 and a high of ₹10,653.05. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Astrazeneca Pharma India Ltd has a market capitalization of approximately 20,622.00. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Astrazeneca Pharma India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 109.97 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 20,622.00 Cr, Astrazeneca Pharma India Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Astrazeneca Pharma India Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Astrazeneca Pharma India Ltd is 109.97. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The company said CDSCO approved Enhertu for an additional indication, allowing it to import, sell and distribute the drug in India for expanded use.
In the provided quarterly table, net income for Mar’25 is ₹58.25 crore and total revenue is ₹480.48 crore.
Biopharma Shakti is a Union Budget 2026 initiative with a 10,000 crore outlay over five years, aiming to boost domestic biopharma manufacturing and R&D. For AstraZeneca Pharma India, this means improved supply chain resilience, potential cost reductions, and faster regulatory approvals for new drugs due to strengthened CDSCO.
Investor Presentation
Q1 FY24
Investor Presentation
Q1 FY23
Investor Presentation
Q1 FY22
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY21
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY19
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
3
Neutral
3
Bullish
8
Bearish
34
Neutral
3
Bullish
9
Bearish
31
Neutral
0
Bullish
1
AstraZeneca Pharma India Limited (APIL) is a subsidiary engaged in manufacturing, distributing, and marketing pharmaceutical products, focusing on therapeutic areas like oncology, cardio metabolic, and respiratory care.
The company has aligned with AstraZeneca PLC’s global therapeutic focus, driving significant market presence in India’s diabetes and cardiovascular segments through strategic partnerships and product launches.
APIL's recent launch of innovative drugs like Transtuzumab Deruxtecan for breast cancer marks its significant entry into advanced oncology treatment.
While regulatory interventions have influenced drug pricing, strategic responses like partnerships with Dr. Reddy's Laboratories and Sun Pharma enhanced APIL’s market access and portfolio reach.
APIL continues its R&D expansion in Bangalore, reinforcing its role within AstraZeneca’s global research network.
Pharmaceuticals & Biotechnology
Pharmaceuticals
20,622 Cr
Low Risk
110.0
34.1
4.6
23.6
10,653.05
7,630.00
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
17143.05 | 21,750 Cr | 59.75 | 11.61 | 0.20 | 19.42 | 23.57 | 12.42 | ||
163.85 | 21,475 Cr | -65.89 | 2.63 | 0.00 | -3.58 | 2.58 | -1.81 | ||
1292.70 | 21,215 Cr | 85.98 | 16.46 | 0.12 | 19.14 | 22.56 | 10.60 | ||
4510.00 | 20,918 Cr | 28.96 | 4.98 | 1.64 | 17.19 | 23.02 | 14.68 | ||
8237.00 | 20,622 Cr | 109.97 | 23.63 | 0.44 | 21.49 | 25.53 | 9.43 | ||
1398.80 | 18,939 Cr | 30.57 | 4.85 | 0.53 | 15.87 | 13.27 | 8.79 | ||
766.10 | 18,911 Cr | 31.78 | 3.72 | 0.23 | 11.70 | 13.63 | 7.71 | ||
| Median: 7 Co. | — | 1398.80 | 20,918 Cr | 31.78 | 4.98 | 0.23 | 17.19 | 22.56 | 9.43 |
Senior management resignations
AstraZeneca Pharma India announced resignations of Ms. Aditi Mehta (Business Unit Director - Oncology) effective COB June 12, 2026, and Mr. Srikanth B.S. (Site Lead, India Operations) effective COB June 15, 2026; replacements being sought.
Senior Management Resignation
AstraZeneca Pharma India announced resignations of Ms. Aditi Mehta (Business Unit Director - Oncology), effective June 12, 2026, and Mr. Srikanth B.S. (Site Lead, India Operations), effective June 15, 2026; replacements being sought.
Regulatory approval
AstraZeneca Pharma India has received CDSCO permission to import Trastuzumab deruxtecan (Enhertu) 100 mg/5mL for use with pertuzumab as first‑line treatment for unresectable/metastatic HER2‑positive breast cancer, enabling marketing in India subject to any further statutory approvals.
Regulatory Approval
AstraZeneca Pharma India received CDSCO permission to import and market Enhertu (trastuzumab deruxtecan) 100 mg/5mL for an additional indication: with pertuzumab as first‑line treatment of unresectable/metastatic HER2‑positive breast cancer, subject to any further statutory approvals.
